ADAR1 Capital Management »

Neurogene shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Neurogene (NGNE) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Neurogene

Tip: Access up to 7 years of quarterly data

All positions including Neurogene held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Neurogene by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $105k 5.4k 19.38

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Neurogene

EcoR1 Capital
Samsara BioCapital
Dr. Jeffrey R. Jay, M.D.
Redmile Group
BlackRock
Henderson Group
Cormorant Asset Management
Arrowpoint Asset Management
Casdin Capital
Vanguard Group
Avidity Partners Management
Baker Bros. Advisors
Walleye Trading Advisors
Susquehanna International
Nantahala Capital Management

View all funds holding Neurogene